糖心原创

Physiology, Pharmacology and Neuroscience
 

Madeleine King

Assistant Professor, Faculty of Medicine & Health Sciences

Contact

Biography

I graduated from the University of Bath in 2002 with a MSci in Pharmacology, which included an industrial placement in the Behavioural Neuroscience department of the Merck Sharp & Dohme Neuroscience Research Centre. I moved to Nottingham to complete a Roche-funded PhD on the role of 5-HT6 receptors in memory and attention, followed by post-doctoral research on a multicentre EU FP6-funded project, developing novel models for glutamatergic CNS disorders using short hairpin RNA approaches. I was appointed as Senior Research Fellow in 2010 and promoted to Assistant Professor in 2023.

I received a 2019 British Association for Psychopharmacology (BAP) in non-clinical psychopharmacology, and from 2019-2023 I was member of the British Journal of Pharmacology Editorial Board . I am BAP until summer 2025.

Expertise Summary

I have expertise in a broad range of behavioural techniques (using the latest software for computerised tracking, visual touchscreen tasks and recording of ultrasonic vocalisations), complimentary molecular approaches and access to state of the art magnetic resonance spectroscopy (MRS).

Teaching Summary

I teach on year 2-4 of the Neuroscience degree, on topics related to my research. I am also a personal tutor and I supervise final year research projects.

I have achieved Fellowship of the Higher Education Academy (FHEA) in recognition of my commitment to professionalism in learning and teaching in higher education.

Research Summary

My research uses neurodevelopmental models to understand how stress and adversity impact on brain function and contribute to cognitive and social dysfunction. The same models are extremely useful for… read more

Selected Publications

  • GOH J-Y, O'SULLIVAN SE, SHORTALL SE, ZORDAN N, PICCININI AM, POTTER HG, FONE KCF and KING MV, 2020. Brain, Behavior, and Immunity. 89, 100-117
  • SHORTALL SE, BROWN AM, NEWTON-MANN E, DAWE-LANE E, EVANS C, FOWLER M and KING MV, 2020. Calbindin deficits may underlie dissociable effects of 5-HT6 and mGlu7 antagonists on glutamate and cognition in a dual-hit neurodevelopmental model for schizophrenia Molecular Neurobiology. (In Press.)
  • KOHLI S, KING MV, WILLIAMS S, EDWARDS A, BALLARD TM, STEWARD LJ, ALBERATI D and FONE KCF, 2019. Neuropsychopharmacology. 44(2), 295-305
  • SHORTALL SE, NEGM OH, FOWLER M, FAIRCLOUGH LC, TIGHE PJ, WIGMORE PM and KING MV, 2018. Molecular Neurobiology. 55(9), 7413-7430

Current Research

My research uses neurodevelopmental models to understand how stress and adversity impact on brain function and contribute to cognitive and social dysfunction. The same models are extremely useful for evaluating novel treatments for conditions like schizophrenia, autism and depression. Our group has a track record of successful collaboration on EU and industry-funded projects evaluating novel therapeutics. Current group members are working on a variety of exciting projects, investigating changes to inflammatory biomarkers in patients with schizophrenia, strategies for optimizing nasal delivery of potential therapeutics, and the impact of stress and inflammation on the gut microbiome-brain axis.

I am always keen to establish new links with academic and industrial researchers - if you are interested please contact me via email.

Future Research

I will be welcoming several new postgraduate students throughout the 2025-26 academic year. Their projects involve:

  1. Developing in vitro models for stress-related mental illnesses
  2. Assessing changes to the gut microbiota in models for stress-related mental illnesses
  3. Investigating biased signalling at the 5-HT6 receptor
  4. Examining nanoparticle approaches to enhance nose-brain delivery of therapeutic peptides
  5. Developing bespoke nanocarriers for controlled encapsulation and release of therapeutic peptides

There may be an additional opportunity for an MRes or self-funded PhD project on 'Validating behavioural tests for social learning/empathy'. Information about applying can be found here.

  • SHORTALL SE, BROWN AM, NEWTON-MANN E, DAWE-LANE E, EVANS C, FOWLER M and KING MV, 2020. Calbindin deficits may underlie dissociable effects of 5-HT6 and mGlu7 antagonists on glutamate and cognition in a dual-hit neurodevelopmental model for schizophrenia Molecular Neurobiology. (In Press.)
  • GOH J-Y, O'SULLIVAN SE, SHORTALL SE, ZORDAN N, PICCININI AM, POTTER HG, FONE KCF and KING MV, 2020. Brain, Behavior, and Immunity. 89, 100-117
  • KOHLI S, KING MV, WILLIAMS S, EDWARDS A, BALLARD TM, STEWARD LJ, ALBERATI D and FONE KCF, 2019. Neuropsychopharmacology. 44(2), 295-305
  • DUNPHY DOHERTY F, O鈥橫AHONY SM, PETERSON VL, O鈥橲ULLIVAN O, CRISPIE F, COTTER PD, WIGMORE P, KING MV, CRYAN JF and FONE KCF, 2018. Brain, Behavior and Immunity. 68, 261-273
  • SHORTALL SE, NEGM OH, FOWLER M, FAIRCLOUGH LC, TIGHE PJ, WIGMORE PM and KING MV, 2018. Molecular Neurobiology. 55(9), 7413-7430
  • SHORTALL SE, GREEN AR, FONE KC and KING MV, 2016. Journal of psychopharmacology (Oxford, England). 30(7), 698-706
  • WATSON DJ, KING MV, GYERTY脕N I, KISS B, ADHAM N and FONE KC, 2016. European Neuropsychopharmacology. 26(2), 208-24
  • SHORTALL SE, SPICER CH, EBLING FJ, GREEN AR, FONE KC and KING MV, 2016. Addiction Biology. 21(6), 1127-1139
  • KING, M.V., KURIAN, N., QIN, S., PAPADOPOULOU, N., WESTERINK, B.H.C., CREMERS, T.I., EPPING-JORDAN, M.P., LE POUL, E., RAY, D.E., FONE, K.C.F., KENDALL, D.A., MARSDEN, C.A. and SHARP, T.V., 2014. Neuropsychopharmacology. 39(2), 464-476
  • GREEN AR, KING MV, SHORTALL SE and FONE KCF, 2014. British Journal of Pharmacology. 171(9), 2251-2268
  • JONES S, FILECCIA EL, MURPHY M, FOWLER MJ, KING MV, SHORTALL SE, WIGMORE PM, GREEN AR, FONE KCF and EBLING FJP, 2014. Neuroscience letters. 559, 34-8
  • WRIGHT TM, KING MV, DAVEY WG, LANGLEY-EVANS SC and VOIGT JW, 2014. The British journal of nutrition. 112, 1933-7
  • SHORTALL, S.E., GREEN, A.R., SWIFT, K.M., FONE, K.C.F. and KING, M.V., 2013. British Journal of Pharmacology. 168(4), 966-977
  • SHORTALL, S.E., MACEROLA, A.E., SWABY, R.T.R., JAYSON, R., KORSAH, C., PILLIDGE, K.E., WIGMORE, P.M., EBLING, F.J.P., GREEN, A.R., FONE, K.C.F. and KING, M.V., 2013. European Neuropsychopharmacology. 23(9), 1085-1095
  • GREEN AR, KING MV, SHORTALL SE and FONE KCF, 2012. British Journal of Pharmacology. 166(5), 1523-36
  • GREEN, A. R., KING, M. V., SHORTALL, S. E. and FONE, K. C. F., 2012. British Journal Of Pharmacology. 166(5), 1521-1522
  • MARSDEN, C.A., KING, M.V. and FONE, K.C.F., 2011. Neuropharmacology. 61(3), 400-407
  • KING, M.V., SPICER, C.H., SLEIGHT, A.J., MARSDEN, C.A. and FONE, K.C.F., 2009. Psychopharmacology. 202(1-3), 111-123
  • KING MV, SEEMAN P, MARSDEN CA and FONE KC, 2009. Synapse (New York, N.Y.). 63(6), 476-83
  • KING M.V, MARSDEN C.A and FONE K.C., 2008. Trends Pharmacol Sci. 29(9), 482-492
  • KING M.V, SLEIGHT A.J, WOOLLEY M.L, TOPHAM I.A, MARSDEN C.A and FONE K.C., 2004. Neuropharmacology. 47(2), 195-204

Physiology, Pharmacology and Neuroscience

School of Life Sciences
糖心原创
Medical School
Queen's Medical Centre
Nottingham NG7 2UH